Loading company
Molecular Partners AG
MOLN · Nasdaq · ·
Next earnings: October 29, 2026
$4.300.0%Sep 25 close
- 1M
- -4.4%
- 6M
- +9.4%
- 1Y
- +15.9%
- 5Y
- -77.6%
MOLN · Nasdaq · ·
Next earnings: October 29, 2026
$4.300.0%Sep 25 close
Molecular Partners AG is scheduled to report next on October 29, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2025 | 3 months toSep 30, 2023 | Change |
|---|---|---|---|
| Total Revenue | $1.9M | $3M | -38.96% |
| Free Cash Flow | -$12M | -$15.9M | +25.05% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Molecular Partners AG has no earnings call transcript available.
“The first half of 2026 was marked by strong execution across our pipeline. With MP0712, a DLL3-targeting Radio-DARPin, we have treated the first patients in our SCLC trial, and dose escalation in the Phase 1/2a study is progressing as planned. To further strengthen our Radio pipeline, we selected CD70 as our next target, which will be evaluated using an isotope-agnostic approach. Backed by a strong balance sheet that funds operations into late 2027, we remain focused on delivering key value-driving milestones, including initial clinical data from MP0712 later this year and continued advancement of our pipeline,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Molecular Partners AG (SIX, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of medicines known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including radiopharmaceuticals for targeted alpha therapy and logic-gated, next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Molecular Partners AG filed on August 25, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.